|
1
|
Heinemann V: Present and future treatment
of pancreatic cancer. Semin Oncol. 29(Suppl 9): 23–31. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Goggins M: Molecular markers of early
pancreatic cancer. J Clin Oncol. 23:4524–4531. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chua YJ and Cunningham D: Adjuvant
treatment for resectable pancreatic cancer. J Clin Oncol.
23:4532–4537. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Real FX: A ‘catastrophic hypothesis’ for
pancreas cancer progression. Gastroenterology. 124:1958–1964. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Nitecki SS, Sarr MG, Colby TV and van
Heerden JA: Long-term survival after resection for ductal
adenocarcinoma of the pancreas. Is it really improving? Ann Surg.
221:59–66. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sohn TA, Yeo CJ, Cameron JL, Koniaris L,
Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH and Lillemoe
KD: Resected adenocarcinoma of the pancreas-616 patients: Results,
outcomes, and prognostic indicators. J Gastrointest Surg.
4:567–579. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bilimoria KY, Bentrem DJ, Ko CY, Tomlinson
JS, Stewart AK, Winchester DP and Talamonti MS: Multimodality
therapy for pancreatic cancer in the U.S.: Utilization, outcomes,
and the effect of hospital volume. Cancer. 110:1227–1234. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Sener SF, Fremgen A, Menck HR and
Winchester DP: Pancreatic cancer: A report of treatment and
survival trends for 100,313 patients diagnosed from 1985–1995,
using the National Cancer Database. J Am Coll Surg. 189:1–7. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Crane CH, Evans DB, Wolff RA, Abbruzzese
JL, Pisters PWT and Janjan NA: The pancreas. Radiation oncology:
rationale, technique, results (8th). Cox J and Ang KK: (Mosby, St
Louis, MO). 456–480. 2003.
|
|
10
|
Mantell BS: Radiotherapy for dysphagia due
to gastric carcinoma. Br J Surg. 69:69–70. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Myint AS: The role of radiotherapy in the
palliative treatment of gastrointestinal cancer. Eur J
Gastroenterol Hepatol. 12:381–390. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Greene FL, Page DL, Fleming ID, Fritz AG,
Balch CM, Haller DG and Morrow M: Digestive system. AJCC Cancer
Staging Manual (6th). (Chicago, IL). Springer. 151–157. 2002.
|
|
13
|
Cancer Therapy Evaluation Program: Common
Terminology Criteria for Adverse Events. version 3.0. DCTD, NCI,
NIH, DHHS. http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdfAccessed.
August 09–2006
|
|
14
|
Krzyzanowska MK, Weeks JC and Earle CC:
Treatment of locally advanced pancreatic cancer in the real word:
population-based practices and effectiveness. J Clin Oncol.
21:3409–3414. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Park JK, Yoon YB, Kim YT, Ryu JK, Yoon WJ
and Lee SH: Survival and prognostic factors of unresectable
pancreatic cancer. J Clin Gastroenterol. 42:86–91. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Rudra S, Narang AK, Pawlik TM, Wang H,
Jaffee EM, Zheng L, Le DT, Cosgrove D, Hruban RH, Fishman EK, et
al: Evaluation of predictive variables in locally advanced
pancreatic adenocarcinoma patients receiving definitive
chemoradiation. Pract Radiat Oncol. 2:77–85. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wild AT, Ye X, Ellsworth SG, et al: The
association between chemoradiation-related lymphopenia and clinical
outcomes in patients with locally advanced pancreatic
adenocarcinoma. Am J Clin Oncol. 38:259–265. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Morganti AG, Trodella L, Valentini V,
Barbi S, Macchia G, Mantini G, Turriziani A and Cellini N: Pain
relief with short-term irradiation in locally advanced carcinoma of
the pancreas. J Palliat Care. 19:258–262. 2003.PubMed/NCBI
|
|
19
|
Lillemoe KD, Cameron JL, Kaufman HS, Yeo
CJ, Pitt HA and Sauter PK: Chemical splanchnicectomy in patients
with unresectable pancreatic cancer. A prospective randomized
trial. Ann Surg. 217:447–457. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wong GY, Schroeder DR, Carns PE, Wilson
JL, Martin DP, Kinney MO, Mantilla CB and Warner DO: Effect of
neurolytic celiac plexus block on pain relief, quality of life, and
survival in patients with unresectable pancreatic cancer: A
randomized controlled trial. JAMA. 291:1092–1099. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Levy MJ and Wiersema MJ: EUS-guided celiac
plexus neurolysis and celiac plexus block. Gastrointest Endosc.
57:923–930. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Huguet F, Goodman KA, Azria D, Racadot S
and Abrams RA: Radiotherapy technical considerations in the
management of locally advanced pancreatic cancer: American-French
consensus recommendations. Int J Radiat Oncol Biol Phys.
83:1355–1364. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Goyal K, Einstein D, Ibarra RA, Yao M,
Kunos C, Ellis R, Brindle J, Singh D, Hardacre J, Zhang Y, et al:
Stereotactic body radiation therapy for nonresectable tumors of the
pancreas. J Surg Res. 174:319–325. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Cascinu S, Falconi M, Valentini V and
Jelic S: ESMO Guidelines Working Group: Pancreatic cancer: ESMO
Clinical Practice Guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 21(Suppl 5): v55–v58. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Asakura H, Hashimoto T, Harada H, Mizumoto
M, Furutani K, Hasuike N, Matsuoka M, Ono H, Boku N and Nishimura
T: Palliative radiotherapy for bleeding from advanced gastric
cancer: Is a schedule of 30 Gy in 10 fractions adequate? J Cancer
Res Clin Oncol. 137:125–130. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wong AA, Delclos ME, Wolff RA, Evans DB,
Abbruzzese JL, Tamm EP, Xiong HQ, Ho L and Crane CH: Pancreatic
Tumor Study Group: Radiation dose considerations in the palliative
treatment of locally advanced adenocarcinoma of the pancreas. Am J
Clin Oncol. 28:227–233. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Royal RE, Levy C, Turner K, Mathur A,
Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, et
al: Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for
locally advanced or metastatic pancreatic adenocarcinoma. J
Immunother. 33:828–833. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Le DT, Lutz E, Uram JN, Sugar EA, Onners
B, Solt S, Zheng L, Diaz LA Jr, Donehower RC, Jaffee EM, et al:
Evaluation of ipilimumab in combination with allogeneic pancreatic
tumor cells transfected with a GM-CSF gene in previously treated
pancreatic cancer. J Immunother. 36:382–389. 2013. View Article : Google Scholar : PubMed/NCBI
|
